FactorPad
Build a Better Process

Stock Risk Measures for Sarepta Therapeutics Inc

A quantitative factor review as of December 31, 2020.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: January 03, 2021
See how we arrive at an overall risk score of 42 for SRPT below.

/ factorpad.com / stocks / f99mrx.html


An ad-free and cookie-free webpage by FactorPad


SRPT Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Sarepta Therapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how SRPT stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs . Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f99mrx.html


SRPT stock risk
SAREPTA THERAPEUTICS INC stock beta
SRPT risk report
SRPT f99mrx
SRPT risk analysis
SRPT volatility
SAREPTA THERAPEUTICS INC credit risk
SRPT liquidity risk
SRPT leverage
SRPT valuation
SRPT systematic risk
SRPT specific risk
SAREPTA THERAPEUTICS INC volatility
SRPT analysis
SRPT financial ratio

This is a new resource, spread the word, tell a friend